• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Cannabis Name Green Thumb Industries Eyes Big Boost From Opioid Substitute Law

New Illinois legislation could signal a potential tidal wave of growth in the budding industry.
By STEVE GELSI Aug 29, 2018 | 12:09 PM EDT
Stocks quotes in this article: GTBIF

Green Thumb Industries (GTBIF) (CSE: GTII) said a new Illinois law to allow cannabis as an alternative pain medication to opioids is expected to have a material positive effect on the legal cannabis business.

The Chicago and Vancouver-based cannabis wholesaler and retailer said the signing of the opioid replacement bill by Gov. Bruce Rauner on Tuesday and similar moves in other states signal a potential tidal wave of growth in the budding industry.

Green Thumb Industries founder and chairman Benjamin Kovler said the company is adding wholesale capacity in Illinois because the new law will "materially impact consumer access to cannabis and grow demand in the state."

Kovler did not provide any specific earnings or revenue targets on its financial performance related to the Illinois law and other measures. But he remained bullish on prospects for cannabis to combat America's opioid epidemic.

Data showing drops in opioid deaths in states with legal cannabis programs has fueled legislative and regulatory changes in Pennsylvania, New York
and Ohio -- all markets where Green Thumb Industries is currently present.

"We think the effect of this is just being learned across the country," Kovler said Tuesday on the company's first analyst call since going public in June on the Canadian Securities Exchange. The company's shares began trading on the U.S. OTC market in July.

Kovler reiterated his bullish comments on cannabis as an opioid substitute in a phone call with Real Money.

In Illinois, the new measure will allow any patient with a prescription for opioids to have access to legal cannabis. The state embraced the law after nearly 2,000 people died in 2016 from opioid overdoses.

On the analyst call, Kovler said he's working to grow market share in the U.S. cannabis business, which could be worth well into the tens of billions a year. Cannabis as a substitute for alcohol and opioids will fuel demand as the business shifts from the illegal market to the legal market, he said.

Looking back at Green Thumb's second-quarter, revenue jumped 291%, year over year, to $13.6 million, and rose 25% from the previous quarter. Second-quarter net income was $400,000, up from a loss of $1.6 million in the first quarter of 2018. Adjusted EBITDA was $500,000 in the second quarter.

During the quarter, Green Thumb added two new directors to its board. Glen T. Senk is the ex-CEO of Urban Outfitters URBN who scaled the Anthropologie retail strategy. Wes Moore is the CEO of Robin Hood, a large New York City poverty-fighting organization. Also on the personnel front, the company hired 150 people during the quarter.

As of June 30, Green Thumb generated wholesale revenue in three out of its eight markets in Illinois, Maryland and Pennsylvania. Nevada, Massachusetts, Florida and New York are in various stages of production.

Green Thumb's retail business is centered on Rise, which currently has 13 stores operating in five markets, with potential expansion for 59 stores.

Looking ahead, the company is building its presence in Florida, Massachusetts, New York and Ohio. It's applying for licenses to operate in New Jersey
and Virginia and studying new markets, including California.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gelsi had no positions in any securities mentioned.

TAGS: Investing | Stocks

More from Stocks

Funko's Not Just Child's Play

Timothy Collins
Dec 5, 2019 12:10 PM EST

The 'toy' company is just too cheap and attractive, right now; plus, those pot stocks are looking to be in a funk.

As Nike Finds Its Footing on Direct Sales, Expect It to Race Higher in 2020

Stephen Guilfoyle
Dec 5, 2019 11:39 AM EST

But if China trade talks fail, this shoe company could get tripped up, so here's how to play it.

Ready, Set, Go: Nike Could Break Out to the Upside

Bruce Kamich
Dec 5, 2019 11:09 AM EST

Let's check the charts and technical indicators before we lace up a recommendation.

Weakness After Protracted Upside Move Causes Discomfort

James "Rev Shark" DePorre
Dec 5, 2019 10:52 AM EST

Some traders seem unsettled by a bit of downside volatility after not experiencing much of it of late.

Here's How I'd Play Nike

Timothy Collins
Dec 5, 2019 10:41 AM EST

Nike is a name that draws a good amount of business from China.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:24 PM EST GARY BERMAN

    Fibocall: The SPX-Cash Long-Term View

    You will hear from many analysts on TV screaming t...
  • 10:35 AM EST BOB LANG

    Added Some Apple

    We'll take advantage of this pullback and add some...
  • 01:50 PM EST BOB LANG

    Added Some HD, MRTX

    We'll add this strong biotech name and a retailer ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login